The contracting authorities shall enter into framework agreements on pharmaceutical products for oncology drugs in accordance with the list of active ingredients (annex. 3), with stated indications on cancer spreads to the skeleton, prostata cancer spreads, basal cell carcinoma, cancer thyroidea and nevus cancer spreads The competition also includes BRAF/MEK- inhibitors.